Expression of p16INK4a, alone or combined with p53, is predictive of better prognosis in colorectal adenocarcinoma in Tunisian patients

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 6, 2011, Pages 562-568

  Miladi Abdennadher, Imen ^a   Abdelmaksoud Damak, Rania ^a   Ayadi, Lobna ^b   Khabir, Abdelmajid ^b   Amouri, Ali ^b   Frikha, Foued ^b   Ellouz, Sameh ^b   Frikha, Mounir ^b   Sellami Boudawara, Tahia ^b   Mokdad Gargouri, Raja ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

colorectal cancer; immunohistochemistry; p16INK4a; p53; prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PARAFFIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DESCENDING COLON; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUNISIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA;

EID: 81755188351     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182143380     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74-108.
2. Sellami A, Sellami-Boudawara T, Hsairi M, et al. Cancers incidence in Sfax region between 2000-2002. Register of cancers in the south of Tunisia. 2007;18-21.
3. Lam AK, Ong K, Ho YH. Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression. Dis Colon Rectum. 2006;49:1275-1283. (Pubitemid 44401375)
4. Lam AK, Ho YH. Primary squamous cell carcinoma of the rectum in a patient on immunosuppressive therapy. Pathology. 2006;38:74-76. (Pubitemid 43259260)
5. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006;127:265-275. (Pubitemid 44572384)
6. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704-707. (Pubitemid 24036021)
8. Marx J. New tumor suppressor may rival p53. Science 1994; 264:344-345. (Pubitemid 24178890)
9. Yuen PW, Man M, Lam KY, et al. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol. 2002;55:58-60. (Pubitemid 34081683)
10. Palmqvist R, Rutegard JN, Bozoky B, et al. Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have upregulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol. 2000;157:1947-1953.
11. McKay JA, Douglas JJ, Ross VG, et al. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol. 2002;196:386-393. (Pubitemid 34262849)
12. Norrie MW, Hawkins NJ, Todd AV, et al. Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol. 2003;84:143-150. (Pubitemid 37363157)
13. Schneider-Stock R, Boltze C, Peters B, et al. Differences in loss of p16INK4 protein expression by promoter methylation between leftand right-sided primary colorectal carcinomas. Int J Oncol. 2003;23: 1009-1013.
14. Tada T, Watanabe T, Kazama S, et al. Reduced p16 expression correlates with lymphatic invasion in colorectal cancers. Hepatogastroenterology. 2003;50:1756-1760. (Pubitemid 37467927)
15. Cui X, Shirai Y, Wakai T, et al. Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma. Hum Pathol. 2004;35:1189-1195. (Pubitemid 39361641)
16. Carneiro FP, Ramalho LN, Britto-Garcia S, et al. Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum. 2006;49:588-594. (Pubitemid 43723805)
17. Zhao P, Mao X, Talbot IC. Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence. World J Gastroenterol. 2006;12:6391-6396. (Pubitemid 44712426)
18. Zhao P, Hu YC, Talbot IC. Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol. 2003;9:2202-2206. (Pubitemid 37321445)
19. Levine AJ, Momand J. The p53 tumor suppressor gene. Nature. 1991;351:453-456.
20. Hsieh JS, Lin SR, Chang MY, et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg. 2005;71:336-343.
21. Soong R, Robbins PD. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol. 1995;27:1050-1055.
22. Wittekind C, Greene FL. TNM Classification of Malignant Tumours. 6th edition. Hoboken, New Jersey: John Wiley and Sons; 2005.
23. Aaltonen LA. WHO Classification of Tumors: Pathology and Genetics of Tumors of Digestive System. Lyon: IARC Press; 2000:105-119.
24. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045-11049.
25. Miladi-Abdenadher I, Abdelmaksoud-Damak R, Ayadi L, et al. Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma. Biosci Rep. 2010;3. [Epub ahead of print].
26. Psofaki V, Kalogera C, Tzambouras N, et al. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J Gastroenterol. 2010;28:3553-3560.
27. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene. 2007;26:2145-2156. (Pubitemid 46536642)
28. Nunes B, Juca MJ, Gomes EG, et al. Metalloproteinase-1, metalloproteinase-7, and p53 immunoexpression and their correlation with clinicopathological prognostic factors in colorectal adenocarcinoma. Int J Biol Markers. 2009;24:156-164.
29. Huh JW, Lee JH, Kim HR. Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: a study of 356 surgically resected cases. Hepatogastroenterology. 2010;57:734-740.
30. Diez M, Medrano M, Muguerza JM, et al. Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res. 2000;3907-3912. (Pubitemid 32002296)
31. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer. 1996;74:216-223. (Pubitemid 26254132)
32. Pereira H, Silva S, Juliao R, et al. Prognostic markers for colorectal cancer: expression of p53 and bcl2. World J Surg. 1997;21:210-213. (Pubitemid 27053444)
33. Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23: 7518-7528. (Pubitemid 46291815)
34. Lan YT, Chang SC, Fen-Yau Li A, et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis. 2007;22:499-506. (Pubitemid 46488054)
35. Pancione M, Forte N, Fucci A, et al. Prognostic role of betacatenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Hum Pathol. 2010;41:867-876.
36. Menezes HL, Jucá MJ, Gomes EG, et al. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors. Arq Gastroenterol. 2010;47:141-147.
37. Sun XF, Carstensen JM, Zhang A, et al. Prognostic significance of cytoplasmatic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992;340:1369-1373.
38. Flamini G, Curigliano G, Ratto C, et al. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer: an immunohistochemical analysis. Eur J Cancer. 1996;32:802-806.
39. Lotter O, Am A, Safi F. Prognostic significance of p53-expression in colorectal carcinoma as measured by a luminometric immunoassay. Ger Med Sci. 2010;8:1-9.
40. Jansson A, Gentile M, Sun XF. P53 mutations are present in colorectal cancer with cytoplasmic p53 accumulation. Int J Cancer. 2001;92:338-341. (Pubitemid 32249708)
41. Gannon JV, Greaves R, Iggo R, et al. Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J. 1990;9:1595-1602.